A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

Abstract

A panel of nine CSF biomarkers was able to differentiate APS from patients with PD and dementia. This may have important clinical utility in improving diagnostic accuracy, allowing better prognostication and earlier access to potential disease-modifying therapies.